Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenovaTSE:9341 -1.32%78 EV-to-EBITDA is 6.31 as of Sep. 12, 2026, which is 33% below its 10-year median of 9.41. GuruFocus rates TSE:9341 with a GF Score™ of 78/100 and a GF Value™ of 円2,056.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 516 Medical Devices & Instruments companies, Genova ranks better than 81.01% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genova's enterprise value is 円7,040 Mil.
Genova's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,115 Mil. Therefore, Genova's EV-to-EBITDA for today is 6.31.
The historical rank and industry rank for Genova's EV-to-EBITDA or its related term are showing as below:
TSE:9341'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.2 Med: 9.41 Max: 83.51
Current: 6.32
During the past 6 years, the highest EV-to-EBITDA of Genova was 83.51. The lowest was 3.20. And the median was 9.41.
TSE:9341's EV-to-EBITDA is ranked better than 81.01% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 13.675
vs TSE:9341: 6.32
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-09-12), Genova's stock price is 円597.00.
Genova's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was 円35.960. Therefore, Genova's PE Ratio (TTM) for today is 16.60.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genova's share price for today is 円597.00.
Genova's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円35.960.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Genova's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:9341 vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Genova's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genova EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Genova's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genova's EV-to-EBITDA falls into.
Genova's current Enterprise Value is 円7,040 Mil.
Genova's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,115 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genova (TSE:9341) has a EV-to-EBITDA of 6.31 as of Sep. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genova. This is 33% below median its historical median of 9.41. Over the past decade, Genova's EV-to-EBITDA has ranged from 3.20 to 83.51. According to the industry distribution chart, Genova ranks #98 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 19%.
Is Genova's EV-to-EBITDA too high?
Genova's current EV-to-EBITDA of 6.31 is 33% below median its 10-year median of 9.41. Over the past 10 years, this metric has ranged from a low of 3.20 to a high of 83.51. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.68. Genova's value of 6.31 is 53.9% below this industry median. Based on the distribution chart, Genova ranks #98 out of 516 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Genova has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Genova's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Genova ranks #98 out of 516 companies for EV-to-EBITDA. This places Genova in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.68. Genova's value of 6.31 is 53.9% below this benchmark. Historically, Genova's own EV-to-EBITDA has ranged from 3.20 to 83.51 over the past decade. While the company's 10-year median is 9.41 vs. the industry median of 13.68, Genova has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.68, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genova's current EV-to-EBITDA of 6.31 is 53.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genova. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genova's current EV-to-EBITDA is 6.31, which is 33% below median its own 10-year median of 9.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genova stock overvalued right now?
Based on GuruFocus' analysis, Genova (TSE:9341) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,056.60, compared to a current price of 円597.00 — trading 71% below its estimated fair value. The current EV-to-EBITDA is 6.31, which is 33% below median its 10-year median of 9.41 and 53.9% below the Medical Devices & Instruments industry median of 13.68. Genova's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Genova (TSE:9341), the current EV-to-EBITDA is 6.31 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genova (TSE:9341) Overvalued in 2026?
Based on GuruFocus' analysis, Genova stock appears to be undervalued.
The current stock price of 円597.00 is trading 71% below its estimated GF Value™ of 円2,056.60.
GuruFocus considers Genova to be Possible Value Trap.
Key valuation signals for TSE:9341:
EV-to-EBITDA: 6.31 (33% below median its 10-year median of 9.41)
GF Value™: 円2,056.60 vs. price of 円597.00 (71% below fair value)
Industry Position: 53.9% below the Medical Devices & Instruments median (#98 of 516)
No single metric tells the full story. See the TSE:9341 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genova Inc manages operations of the medical information site and sales of automatic reception and payment machines for clinics. The group operates in two reportable segments: Medical Platform Business and the Smart Clinic Project. The majority of its revenue is generated from the Medical Platform Business, which operates an online media site (Medical Dock) that provides preventive information and health knowledge to users (patients) on diseases and symptoms. In addition, it also supports users in finding a family doctor that suits them. The Smart Clinic Business develops and provides services that improve the convenience and efficiency of non-medical procedures at medical institutions.
78GF Score
Get the complete analysis for TSE:9341
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9341 has been successfully added to your 
